Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients

Completed · Phase 4

Conditions studied: Gastrointestinal Symptoms, Heart Transplantation

In brief

Mycophenolate sodium (Myfortic®) is a newly developed enteric-coated tablet version of mycophenolate mofetil (Cellcept®) which is currently used as therapy for the prevention of transplant rejection. Myfortic® was developed to improve the gastrointestinal tolerability of Cellcept®. The new enteric-coated, Myfortic® is presently FDA approved for the prevention of acute kidney rejection only. There is no clinical data of its use in heart transplant patients.

Key facts

Study ID
NCT00574197
Run by
Cedars-Sinai Medical Center
People needed
11
Starts
2006-06-01
Expected to finish
2009-12-01
Last updated by the study team
2020-07-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.